B2M and neoplasm: Consistent with these findings, the Voest’s laboratory recently demonstrated that MSI-high tumours with loss of B2M still respond to ICB, and that this effect was associated with an elevated frequency of activated γδ T cells in ICB-naïve tumours and an increased presence of γδ T cells in the tumour microenvironment after ICB treatment [47].